Mankind Pharma reports 24.5% revenue growth in Q1 FY26, declares interim dividend
The announcement of Q1 FY26 financial results, including significant revenue growth, improved EBITDA margin, and an interim dividend, provides crucial information for investors and is likely to have a substantial impact on stock perception and valuation.
The company reported strong revenue growth of 24.5% and an improved EBITDA margin. The management expressed confidence in future performance and declared an interim dividend, indicating a positive outlook despite a decline in PAT.
* Mankind Pharma announced its consolidated financial results for the first quarter ended June 30, 2025 (Q1 FY26). * Revenue from Operations stood at INR 3,570 crore, marking a 24.5% year-on-year (YoY) increase. * Domestic revenue grew by 18.9% YoY to INR 3,101 crore, while exports surged by 81.1% YoY to INR 469 crore, primarily due to the consolidation of BSV. * EBITDA margin improved by 20 basis points YoY to 23.8%, with EBITDA at INR 850 crore. * Profit After Tax (PAT) was INR 445 crore, down 17.4% YoY, with a PAT margin of 12.5%. * Diluted EPS was INR 10.6, a decrease of 20.1% YoY. * In the domestic business, market share increased from 4.8% in March 2025 to 4.9% as of June 2025, driven by outperformance in the Indian Pharmaceutical Market (IPM). * Q1 FY26 secondary sales growth was 9.2% compared to IPM's 8.6%, with volume growth of 2.5% against IPM's 1.4%. * The company saw strong growth in respiratory (17.8%) and anti-infectives (9.1%) segments, and continued outperformance in chronic categories like Cardiology and Anti-Diabetics. * The Consumer Healthcare business recorded strong revenue growth of 15.0% YoY, with key brands like Gas-o-fast (36%), Manforce Condom (18%), HealthOk (15%), and Preganews (12%) showing robust secondary sales growth. * Mr. Rajeev Juneja, Vice Chairman & Managing Director, stated that the revenue growth was led by continued 1.4x outperformance in the Chronic segment, strong growth in the Consumer segment, and BSV consolidation. He expressed confidence in delivering healthy performance for the year. * The company's Board approved an interim dividend of ₹1 per share.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.